Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Auditor change
Notes underwriting agrmnt
Inv. presentation
Quarterly results
Appointed director
Fibrocell Science, Inc. (FCSC) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/13/2019 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Amended and Restated Certificate of Incorporation of the Company",
"Amended and Restated Bylaws of the Company"
12/10/2019 8-K Quarterly results
09/26/2019 8-K/A Submission of Matters to a Vote of Security Holders
09/13/2019 8-K Quarterly results
09/12/2019 8-K Quarterly results
08/22/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "EMPLOYMENT AGREEMENT This Employment Agreement , is entered into as of August 20, 2019 , by and between Fibrocell Science, Inc., a Delaware corporation , and Sean D. Buckley .",
"AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement , is entered into as of August 20, 2019 , by and between Fibrocell Science, Inc., a Delaware corporation , and John Maslowski ."
08/15/2019 8-K Quarterly results
07/02/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Corporate Presentation July 1, 2019"
06/14/2019 8-K Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
Docs: "FIBROCELL SCIENCE, INC. 2019 EQUITY INCENTIVE PLAN Effective as of June 12, 2019 1. Purpose and Objectives",
"FIBROCELL SCIENCE, INC. 2019 EQUITY INCENTIVE PLAN",
"FIBROCELL SCIENCE, INC. 2019 EQUITY INCENTIVE PLAN",
"FIBROCELL SCIENCE, INC. 2019 EQUITY INCENTIVE PLAN"
05/29/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Fibrocell Receives FDA Regenerative Medicine Advanced Therapy Designation for FCX-007 Gene Therapy for the Treatment of RDEB",
"Corporate Presentation May 29, 2019"
05/15/2019 8-K Quarterly results
Docs: "Fibrocell Reports First Quarter 2019 Financial Results and Recent Operational Highlights",
"Corporate Presentation May 15, 2019"
04/16/2019 8-K Quarterly results
03/27/2019 8-K Quarterly results
Docs: "Fibrocell Announces Positive Feedback from Type B End-of-Phase 2 Meeting with FDA on Phase 3 Clinical Trial Design for FCX-007",
"Corporate Presentation March 27, 2019"
01/08/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "Corporate Presentation January 8, 2019"
12/11/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Investment from EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation"
11/13/2018 8-K Quarterly results
Docs: "Costs for the FCX-013",
"Corporate Presentation November 13, 2018"
10/25/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007"
10/03/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Corporate Presentation October 3, 2018"
09/25/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis Bullosa"
09/05/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized Scleroderma EXTON, PA",
"Corporate Presentation September 5, 2018"
08/09/2018 8-K Quarterly results
Docs: "Fibrocell Reports Second Quarter 2018 Financial Results and Recent Highlights",
"Corporate Presentation August 9, 2018"
07/05/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED",
"NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED",
"Board of Directors Fibrocell Science, Inc. 405 Eagleview Boulevard Exton, Pennsylvania 19341 Ladies and",
"ARTICLE II. PURCHASE AND SALE 2.1",
"Million Registered Direct Offering Priced At-the-Market EXTON, PA"
06/22/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/12/2018 8-K Other Events
05/31/2018 8-K Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and E...
Docs: "NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED",
"NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED",
"Board of Directors Fibrocell Science, Inc. 405 Eagleview Boulevard Exton, Pennsylvania 19341 Ladies and",
"ARTICLE II. PURCHASE AND SALE 2.1",
"Million Registered Direct Offering Priced At-the-Market EXTON, PA"
05/24/2018 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "CERTIFICATE OF AMENDMENT OF THE RESTATED CERTIFICATE OF INCORPORATION OF",
"Shares of Common Stock Will Begin Trading on Split-Adjusted Basis on May 25, 2018 EXTON, PA"
05/21/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa"
05/18/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "FCX-007 Interim Data Update"
05/10/2018 8-K Quarterly results
Docs: "Fibrocell Reports First Quarter 2018 Financial Results and Recent Highlights",
"Corporate Presentation May 10, 2018"
04/18/2018 8-K Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits
Docs: "of the U.S. Private Securities Litigation Reform Act of 1995. All"
03/19/2018 8-K Quarterly results
Docs: "Company to Host Conference Call and Webcast Today",
"Private Securities Litigation Reform Act of 1995. All"
03/06/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Announces FDA Allowance of Investigational New Drug Application for FCX-013",
"Private Securities Litigation Reform Act of 1995. All"
02/12/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Private Securities Litigation Reform Act of 1995. All"
02/05/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "Announces Submission of Investigational New Drug Application for FCX-013",
"Private Securities Litigation Reform Act of 1995. All"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy